Sage Therapeutics (NASDAQ: SAGE) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Sage reported 2Q20 results this morning, with focus on the progress they are making with their pipeline, most notably zuranolone, more than the financial performance. Higher R&D expenses led to a $3M greater net loss than we had expected, but positive developments include the start of two Phase 3 trials for zuranolone (in PPD and episodic treatment of MDD), with the acute RRT trial on track to start later this year. Six-month open-label follow-up from the MOUNTAIN trial shows an encouraging durability of response, but without mention of how patients on placebo did over a similar time period. We look for more color on this new data and multiple upcoming catalysts on the conference call.”
To request access to the full report, visit http://nnw.fm/SaZ9d
About Sage Therapeutics, Inc.
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.SageRX.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork